Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)

NCT07205887 is registered in ClinicalTrials.gov with EyeBiotech Ltd. as lead sponsor.

NCT NCT07205887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07205887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)
Lead sponsor
EyeBiotech Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
September 12, 2025
Completion date
June 30, 2028
Enrollment
160 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

branch retinal vein occlusion (brvo), neovascular age-related macular degeneration (nvamd)